Biofrontera Reports Record Revenue in FY 2025 Earnings Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Source: seekingalpha
- Significant Revenue Growth: Biofrontera achieved record annual revenues of $41.7 million in FY 2025, with Q4 revenue reaching $17.1 million, representing a 36% increase compared to Q4 2024, highlighting the company's strong performance and growing adoption in the dermatology market.
- Acquisition Agreement Finalized: The company completed an asset purchase agreement with Biofrontera AG, acquiring all U.S. rights and patents for Ameluz and RhodoLED, with a new royalty structure reducing rates to 12% for annual sales below $65 million and 15% above, significantly lowering the previous 25%-35% transfer pricing model.
- Positive Clinical Progress: Biofrontera submitted a supplemental NDA for sBCC with a PDUFA target action date of September 2026, and positive Phase III results for actinic keratosis, with plans to file a supplemental NDA in Q3 2026 to expand Ameluz's indications, indicating robust pipeline advancement.
- Margin Improvement: The gross profit margin improved from 58% to 82% in Q4 2025, with net income of $5.6 million compared to a net loss of $1.4 million in the prior year, and the company expects gross margins to range between 80% and 85% in 2026, reflecting successful cost structure transformation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFRI
Wall Street analysts forecast BFRI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.860
Low
3.00
Averages
6.00
High
9.00
Current: 0.860
Low
3.00
Averages
6.00
High
9.00
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biofrontera to Participate in Investor Conference
- Webcast Schedule: Biofrontera will host a webcast on May 28, 2026, at 11:00 a.m. ET, accessible via their website, which is expected to attract significant investor interest and enhance the company's visibility in the capital markets.
- One-on-One Meeting Opportunities: Management will participate in virtual one-on-one meetings during the event, allowing potential investors to gain deeper insights into the company's strategies and products, thereby fostering investor relations.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT) with its Ameluz® and RhodoLED® products targeting actinic keratosis, and plans to expand clinical trials to treat non-melanoma skin cancers and moderate-to-severe acne, further solidifying its market position.
- Market Potential: With increasing demand for skin condition treatments, Biofrontera's product portfolio is poised for significant growth in the coming years, particularly in skin cancer prevention, aligning with global health trends.
See More
Biofrontera Q1 Earnings Report Analysis
- Disappointing Earnings: Biofrontera reported a Q1 GAAP EPS of -$0.41, missing expectations by $0.33, indicating pressure on profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 17.4% year-over-year revenue increase to $10.1M, the figure fell short of expectations by $0.4M, suggesting that market demand did not meet anticipated levels, potentially impacting future sales strategies.
- Improved Operating Loss: The operating loss for Q1 was $4.3 million, an improvement from $4.5 million in the same quarter last year, reflecting some progress in cost control that may lay the groundwork for future profitability.
- Stable Cash Flow Position: As of March 31, 2026, the operating cash balance stood at $6.3 million, significantly up from $1.8 million a year earlier, indicating improvements in cash management that support the goal of achieving cash flow breakeven in 2026.
See More
Biofrontera Inc. Reports Strong Q1 2026 Earnings with 80% Gross Margin
- Significant Revenue Growth: Biofrontera Inc. reported product revenues of $10.1 million in Q1 2026, representing a 17% increase from $8.6 million in Q1 2025, demonstrating the effectiveness of the company's business transformation under the new cost structure.
- Gross Margin Improvement: The gross margin increased to approximately 80% from 62% in the prior year quarter, reflecting not only improved product sales but also successful cost control measures that enhance future profitability.
- Near-Zero Operating Cash Flow: The company reported operational cash usage of just $70,000 in Q1, indicating strong cost management and positioning the company to achieve cash flow breakeven in 2026, which boosts investor confidence.
- Compliance Restoration: On May 6, 2026, Biofrontera received written notification from NASDAQ confirming compliance with the Minimum Bid Price Requirement, as the stock price remained above $1 per share for 10 consecutive trading days, reflecting market recognition of the company's outlook.
See More
Biofrontera Reports Strong Q1 2026 Financial Results and Updates
- Significant Revenue Growth: In Q1 2026, Biofrontera reported revenues of $10.1 million, reflecting a 17% year-over-year increase primarily driven by a 16% rise in Ameluz unit sales and a price increase implemented in Q4 2025, thereby enhancing the company's competitive position in the dermatology market.
- Margin Improvement: The gross margin surged from approximately 62% in Q1 2025 to about 80%, an 18 percentage point increase, indicating the successful implementation of the new earnout structure following the strategic transaction, which further improves the company's financial health.
- Clinical Trial Advancements: The company announced positive and statistically significant results from its Phase 3 clinical trial of Ameluz®PDT for treating mild to moderate actinic keratoses, meeting the primary endpoint, which is expected to provide strong support for future market expansion.
- Compliance Restoration: Biofrontera regained compliance with the Nasdaq Minimum Bid Price Requirement as confirmed on May 6, 2026, marking a restoration of stability in the capital markets and investor confidence, which lays a solid foundation for future financing and growth.
See More
Biofrontera Reports Record Q4 2025 Revenue of $17.1M
- Significant Revenue Growth: Biofrontera reported Q4 2025 revenue of $17.1 million, a 36% year-over-year increase, indicating strong market demand and sales performance, which further solidifies its position in the dermatology treatment sector.
- Gross Margin Improvement: The company achieved a gross margin of 82.4%, primarily due to an improved cost structure following its transaction with Biofrontera AG, which not only enhances profitability but also provides funding for future investments and expansion.
- Net Income Turnaround: The net income for Q4 was $5.6 million, compared to a loss in the previous year, reflecting improved operational efficiency and financial health, which boosts investor confidence.
- Positive Future Outlook: Management expects to achieve profitability and cash flow breakeven in 2026, indicating confidence in sustained growth and plans to optimize operations and market strategies to reach this goal.
See More
Biofrontera Reports Record Revenue in FY 2025 Earnings Call
- Significant Revenue Growth: Biofrontera achieved record annual revenues of $41.7 million in FY 2025, with Q4 revenue reaching $17.1 million, representing a 36% increase compared to Q4 2024, highlighting the company's strong performance and growing adoption in the dermatology market.
- Acquisition Agreement Finalized: The company completed an asset purchase agreement with Biofrontera AG, acquiring all U.S. rights and patents for Ameluz and RhodoLED, with a new royalty structure reducing rates to 12% for annual sales below $65 million and 15% above, significantly lowering the previous 25%-35% transfer pricing model.
- Positive Clinical Progress: Biofrontera submitted a supplemental NDA for sBCC with a PDUFA target action date of September 2026, and positive Phase III results for actinic keratosis, with plans to file a supplemental NDA in Q3 2026 to expand Ameluz's indications, indicating robust pipeline advancement.
- Margin Improvement: The gross profit margin improved from 58% to 82% in Q4 2025, with net income of $5.6 million compared to a net loss of $1.4 million in the prior year, and the company expects gross margins to range between 80% and 85% in 2026, reflecting successful cost structure transformation.
See More
Biofrontera to Participate in Investor Conference
- Webcast Schedule: Biofrontera will host a webcast on May 28, 2026, at 11:00 a.m. ET, accessible via their website, which is expected to attract significant investor interest and enhance the company's visibility in the capital markets.
- One-on-One Meeting Opportunities: Management will participate in virtual one-on-one meetings during the event, allowing potential investors to gain deeper insights into the company's strategies and products, thereby fostering investor relations.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT) with its Ameluz® and RhodoLED® products targeting actinic keratosis, and plans to expand clinical trials to treat non-melanoma skin cancers and moderate-to-severe acne, further solidifying its market position.
- Market Potential: With increasing demand for skin condition treatments, Biofrontera's product portfolio is poised for significant growth in the coming years, particularly in skin cancer prevention, aligning with global health trends.
See More
Biofrontera Q1 Earnings Report Analysis
- Disappointing Earnings: Biofrontera reported a Q1 GAAP EPS of -$0.41, missing expectations by $0.33, indicating pressure on profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 17.4% year-over-year revenue increase to $10.1M, the figure fell short of expectations by $0.4M, suggesting that market demand did not meet anticipated levels, potentially impacting future sales strategies.
- Improved Operating Loss: The operating loss for Q1 was $4.3 million, an improvement from $4.5 million in the same quarter last year, reflecting some progress in cost control that may lay the groundwork for future profitability.
- Stable Cash Flow Position: As of March 31, 2026, the operating cash balance stood at $6.3 million, significantly up from $1.8 million a year earlier, indicating improvements in cash management that support the goal of achieving cash flow breakeven in 2026.
See More
Biofrontera Inc. Reports Strong Q1 2026 Earnings with 80% Gross Margin
- Significant Revenue Growth: Biofrontera Inc. reported product revenues of $10.1 million in Q1 2026, representing a 17% increase from $8.6 million in Q1 2025, demonstrating the effectiveness of the company's business transformation under the new cost structure.
- Gross Margin Improvement: The gross margin increased to approximately 80% from 62% in the prior year quarter, reflecting not only improved product sales but also successful cost control measures that enhance future profitability.
- Near-Zero Operating Cash Flow: The company reported operational cash usage of just $70,000 in Q1, indicating strong cost management and positioning the company to achieve cash flow breakeven in 2026, which boosts investor confidence.
- Compliance Restoration: On May 6, 2026, Biofrontera received written notification from NASDAQ confirming compliance with the Minimum Bid Price Requirement, as the stock price remained above $1 per share for 10 consecutive trading days, reflecting market recognition of the company's outlook.
See More
Biofrontera Reports Strong Q1 2026 Financial Results and Updates
- Significant Revenue Growth: In Q1 2026, Biofrontera reported revenues of $10.1 million, reflecting a 17% year-over-year increase primarily driven by a 16% rise in Ameluz unit sales and a price increase implemented in Q4 2025, thereby enhancing the company's competitive position in the dermatology market.
- Margin Improvement: The gross margin surged from approximately 62% in Q1 2025 to about 80%, an 18 percentage point increase, indicating the successful implementation of the new earnout structure following the strategic transaction, which further improves the company's financial health.
- Clinical Trial Advancements: The company announced positive and statistically significant results from its Phase 3 clinical trial of Ameluz®PDT for treating mild to moderate actinic keratoses, meeting the primary endpoint, which is expected to provide strong support for future market expansion.
- Compliance Restoration: Biofrontera regained compliance with the Nasdaq Minimum Bid Price Requirement as confirmed on May 6, 2026, marking a restoration of stability in the capital markets and investor confidence, which lays a solid foundation for future financing and growth.
See More
Biofrontera Reports Record Q4 2025 Revenue of $17.1M
- Significant Revenue Growth: Biofrontera reported Q4 2025 revenue of $17.1 million, a 36% year-over-year increase, indicating strong market demand and sales performance, which further solidifies its position in the dermatology treatment sector.
- Gross Margin Improvement: The company achieved a gross margin of 82.4%, primarily due to an improved cost structure following its transaction with Biofrontera AG, which not only enhances profitability but also provides funding for future investments and expansion.
- Net Income Turnaround: The net income for Q4 was $5.6 million, compared to a loss in the previous year, reflecting improved operational efficiency and financial health, which boosts investor confidence.
- Positive Future Outlook: Management expects to achieve profitability and cash flow breakeven in 2026, indicating confidence in sustained growth and plans to optimize operations and market strategies to reach this goal.
See More
Biofrontera Reports Record Revenue in FY 2025 Earnings Call
- Significant Revenue Growth: Biofrontera achieved record annual revenues of $41.7 million in FY 2025, with Q4 revenue reaching $17.1 million, representing a 36% increase compared to Q4 2024, highlighting the company's strong performance and growing adoption in the dermatology market.
- Acquisition Agreement Finalized: The company completed an asset purchase agreement with Biofrontera AG, acquiring all U.S. rights and patents for Ameluz and RhodoLED, with a new royalty structure reducing rates to 12% for annual sales below $65 million and 15% above, significantly lowering the previous 25%-35% transfer pricing model.
- Positive Clinical Progress: Biofrontera submitted a supplemental NDA for sBCC with a PDUFA target action date of September 2026, and positive Phase III results for actinic keratosis, with plans to file a supplemental NDA in Q3 2026 to expand Ameluz's indications, indicating robust pipeline advancement.
- Margin Improvement: The gross profit margin improved from 58% to 82% in Q4 2025, with net income of $5.6 million compared to a net loss of $1.4 million in the prior year, and the company expects gross margins to range between 80% and 85% in 2026, reflecting successful cost structure transformation.
See More
